Top Markets
Coin of the day
Coeptis Therapeutics Holdings, Inc. Coeptis Therapeutics Holdings, Inc.

Coeptis Therapeutics Holdings, Inc.

COEP
Classement en actions #28028
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates... Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company’s product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze cancer patients if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a chimeric antigen receptor (CAR) therapy for treatment for cancer. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson’s Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Prix de l'action
$4.81
Dernière synchronisation: 2026-07-27
Capitalisation boursière
$29.01M
Changement (1 jour)
-8.56%
Changement (1 an)
-64.66%
Pays
US
Échange Coeptis Therapeutics Holdings, Inc. (COEP)

Catégorie

Ratio P/B pour Coeptis Therapeutics Holdings, Inc. (COEP)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Coeptis Therapeutics Holdings, Inc., le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour Coeptis Therapeutics Holdings, Inc. de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
6.3419 -
US
3.7087 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH